Johnson & Johnson reported strong first-quarter results with significant growth in both Innovative Medicine and MedTech segments, improved adjusted earnings, and positive guidance updates. The acquisition of Shockwave Medical and a continued increase in dividend further enhance investor confidence. Managementâ€™s optimistic tone and strategic expansions suggest the stock is likely to rally in the short term.

[2]